Education
About Us
Working with TipRanks
Follow Us
AbCellera Biologics (ABCL)
NASDAQ:ABCL
ABCL Stock Chart & Stats
$4.27
-$0.28(-8.54%)
At close: 4:00 PM EST
$4.27
-$0.28(-8.54%)
Day’s Range― - ―
52-Week Range$1.89 - $6.52
Previous CloseN/A
Volume1.71M
Average Volume (3M)3.34M
Market Cap
$1.35B
Enterprise Value$1.12B
Total Cash (Recent Filing)$520.67M
Total Debt (Recent Filing)$137.05M
Price to Earnings (P/E)―
Beta1.52
Next Earnings
Feb 24, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.19
Shares Outstanding299,335,050
10 Day Avg. Volume4,081,432
30 Day Avg. Volume3,343,592
Financial Highlights & Ratios
PEG Ratio-0.68
Price to Book (P/B)0.82
Price to Sales (P/S)29.91
P/FCF Ratio-4.61
Enterprise Value/Market Cap0.83
Enterprise Value/Revenue31.84
Enterprise Value/Gross Profit39.80
Enterprise Value/Ebitda-6.04
Forecast
1Y Price Target
$6.67Price Target Upside56.21% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Liquidity And RunwayA cash balance of about $680 million provides financial runway to fund clinical development and strategic programs within the proprietary pipeline.
Manufacturing CapacityCommissioning of a GMP facility creates scalable manufacturing capability to support advancement and potential commercialization of multiple clinical and preclinical antibody programs.
Pipeline StrategyShift toward an internal pipeline focused on two antibody therapeutics positions the company to capture higher-margin opportunities and reduce dependence on external partners.
Bears Say
Clinical Delivery UncertaintyUncertainty over whether ABCL635 can deliver sufficient antibody to target KNDy neurons creates a material biological risk that could impede clinical progress.
Investment RiskA speculative risk designation highlights elevated uncertainty that may reduce investor appetite and pressure valuation multiples.
Partner Revenue VisibilityA reduced number of partnered programs has stepped down partnered business valuation, and expected declines in research fees could weaken near-term revenue visibility.
AbCellera Biologics News
ABCL FAQ
What was AbCellera Biologics’s price range in the past 12 months?
AbCellera Biologics lowest stock price was $1.89 and its highest was $6.51 in the past 12 months.
What is AbCellera Biologics’s market cap?
AbCellera Biologics’s market cap is $1.35B.
When is AbCellera Biologics’s upcoming earnings report date?
AbCellera Biologics’s upcoming earnings report date is Feb 24, 2026 which is in 41 days.
How were AbCellera Biologics’s earnings last quarter?
AbCellera Biologics released its earnings results on Nov 06, 2025. The company reported -$0.19 earnings per share for the quarter, missing the consensus estimate of -$0.139 by -$0.051.
Is AbCellera Biologics overvalued?
According to Wall Street analysts AbCellera Biologics’s price is currently Undervalued.
Does AbCellera Biologics pay dividends?
AbCellera Biologics does not currently pay dividends.
What is AbCellera Biologics’s EPS estimate?
AbCellera Biologics’s EPS estimate is -0.15.
How many shares outstanding does AbCellera Biologics have?
AbCellera Biologics has 299,335,050 shares outstanding.
What happened to AbCellera Biologics’s price movement after its last earnings report?
AbCellera Biologics reported an EPS of -$0.19 in its last earnings report, missing expectations of -$0.139. Following the earnings report the stock price went down -13.687%.
Which hedge fund is a major shareholder of AbCellera Biologics?
Currently, no hedge funds are holding shares in ABCL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AbCellera Biologics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.67 (56.21% Upside)
$6.67 (56.21% Upside)
Blogger Sentiment
Bullish
ABCL Sentiment 66%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 1.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $178.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 1.6%
Last 30 Days ▼ 1.5%
Last 30 Days ▼ 1.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
54.79%
12-Months-Change
Fundamentals
Return on Equity
-16.81%
Trailing 12-Months
Asset Growth
-2.64%
Trailing 12-Months
Company Description
AbCellera Biologics
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
ABCL Company Deck
ABCL Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlights AbCellera's successful transition to a clinical-stage biotech and strong liquidity position, but also notes increased net loss and R&D expenses. While revenue has increased, the stagnation in partner-initiated programs presents a challenge.View all ABCL earnings summariesABCL Revenue Breakdown
93.51% Research fees
3.94% Royalty revenue
2.55% Milestone payments
ABCL Stock 12 Month Forecast
Average Price Target
$6.67
▲(56.21% Upside)
Technical Analysis
Syndax Pharmaceuticals
―
Arcus Biosciences
―
Dianthus Therapeutics
―
Edgewise Therapeutics
―
Structure Therapeutics, Inc. Sponsored ADR
―
Ownership Overview
41.61% Insiders
4.83% Mutual Funds
0.02% Other Institutional Investors
52.22% Public Companies and Individual Investors